TMCnet News
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday October 8, 2020 at 8:00 AMMIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8:00 AM Eastern time. The access information for the investor conference call is as follows: Program Title: NuGenerex Immuno-Oncology - Investor Conference Call Agenda
On the call, Generex President & Chief Executive Officer, Joseph Moscato and his team will provide an overview of NuGenerex Immuno-Oncology and the company’s development efforts for a COVID-19 vaccine using the Ii-key technology to create a “Complete Vaccine” that activates a targeted, neutralizing antibody response and a cellular response that can provide the long term immune memory that is essential to stopping this devastating pandemic. Mr. Moscato said, “I look forward to speaking with our shareholders to discuss the listing of NuGenerex Immuno-Oncology on a national exchange and our plans to expand the Ii-Key tecnology platform to generate new immunotherapies and vaccines. We have a number of exciting initiatives that I am eager to present, and our closing of the Bintai Kinden licensing and distribution agreement for our COVID-19 Complete Vaccine. We are excited that we now have the money to advance our Ii-Key vaccine through the clinical and regulatory process, and as always, we welcome questions from shareholders during the call.” About NuGenerex Immuno-Oncology About Generex Biotechnology Corp. Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. Generex Contact: Generex Biotechnology Corporation Joseph Moscato Todd Falls
|